An online platform that offers public and private companies, across multiple industries the ability to stay active and engaged with the investment community.
Virtual Investor is proud to welcome @RedHillBio Biopharma to our platform!
Another exciting addition to our lineup of innovative companies, bringing fresh opportunities for investors to connect with the stories shaping the market.
Learn more: https://t.co/zaTAWyAhVa
$RDHL
$RDHL highlights strategic transformation and expanded commercial growth strategy in Virtual Investor “What This Means” segment.
Access the segment: https://t.co/Bp9FwBS4yN
Full #RDHL PR: https://t.co/bR0vYCIgwQ
#WTM - Strategic Transformation - Guy Goldberg, CBO of $RDHL, discusses the Company's evolution into a more scalable commercial-stage business, opportunities to drive growth across its expanded GI portfolio and its long-term vision for shareholder value.
https://t.co/rhdptk8M2M
Hear from $AKTX Chief Business Officer Vatnak Vat-Ho in the latest Virtual Investor "What This Means" segment as he discusses his decision to join Akari, the potential of its PH1 payload and strategic priorities for advancing the Company.
🔗: https://t.co/Vwq5geKGQP
Hear from $DARE CEO Sabrina Johnson in the latest Virtual Investor "What This Means" segment as she discusses the new White House Executive Order on women's health, its potential significance and Daré's efforts to address unmet needs in women's health.
🔗 https://t.co/Y3J0MDVNHv
Hear from $ERNA’s team in the latest Virtual Investor "What This Means" segment as they discuss 3 key areas central to Ernexa’s next phase of development: regulatory alignment, scientific differentiation and progress toward first-in-human evaluation.
🔗: https://t.co/Fpt7viBT9Q
🔔Happening Today at 4 PM ET!
Don't miss $ERNA live during its #VirtualInvestor Closing Bell segment for the latest corporate updates, recent progress highlights, and a look at upcoming priorities.
Watch live here: https://t.co/Hd4I4KU2uO
#CellTherapy#Hope#DeliveringHope
Tune In Tomorrow at 4 PM ET
Hear from Ernexa Therapeutics CEO Sanjeev Luther during a live #VirtualInvestor Closing Bell segment as he discusses recent developments and what's ahead for $ERNA.
Don't miss it: https://t.co/Hd4I4KU2uO
#CellTherapy#Oncology#Hope#DeliveringHope
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series on Thursday, October 15th at 4:00 PM ET
https://t.co/JkD0jqHS36
$ERNA #OvarianCancer#CancerResearch#DeliveringHope
📅 Save The Date!
$ERNA will take part in a #VirtualInvestor Closing Bell segment on Thursday, October 15 at 4 PM ET. Tune in to hear key updates from CEO Sanjeev Luther.
Register Here: https://t.co/Hd4I4KU2uO
#CellTherapy#Oncology#Hope#DeliveringHope
Hear from $OTLK CFO Kevin Lundquist in the latest Virtual Investor "What This Means" segment as he discusses joining Outlook Therapeutics following FDA approval and the Company’s path forward toward U.S. commercialization.
Watch here: https://t.co/RWHe6B6e27
#Ophthalmology
$OTLK CEO Bob Jahr joins Virtual Investor’s “CEO Connect” to discuss the FDA approval and its plans for its U.S. commercial launch and the opportunity ahead in the wet AMD market.
Watch here: https://t.co/b0MrjrOQ6y
@OutlookTx#WetAMD
$CNSP Chief Business Officer, Dylan Wenke, joins Virtual Investor’s “What This Means” series to discuss the Company’s business development strategy as it builds an oncology or neurology pipeline with best-in-class potential.
🔗 https://t.co/ElsDBlZShk
@cns_pharma
Virtual Investor Launches "Why Now" On-Demand Conference Featuring Public Company CEOs
Nine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?
Access the Conference Here: https://t.co/P8UG4PT81E
$AIM $AKTX $CNSP $DARE $NVNO $ERNA $GRI
$MBRX $OTLK @AimImmuno@AkariTX@cns_pharma@DareBioscience@enVVenoMedical@ErnexaTx@GRI_BIO@moleculinbio@OutlookTx
Restoring vision means restoring possibility.
Hear CEO Bob Jahr discuss why this is an exciting time for Outlook Therapeutics and its mission to expand retinal treatment options.
Watch the Virtual Investor Why Now Series: https://t.co/0blLIkswbn
@OutlookTx#ClinicalInsights #RetinaResearch #DataUpdates #EyeHealth $OTLK #VirtualInvestor
Some of the biggest challenges in cancer require bold thinking.
CEO Walter Klemp explains why Moleculin is focused on developing new therapies for patients with limited treatment options.
Watch the Virtual Investor Why Now Series: https://t.co/8eVhO4ms7a
@MoleculinBio $MBRX #AML #AcuteMyeloidLeukemia #CancerResearch #VirtualInvestor
New discoveries have the power to change lives.
CEO Marc Hertz shares why targeting NKT cell biology could open new possibilities for patients with inflammatory and fibrotic diseases.
Watch the Virtual Investor Why Now Series: https://t.co/xrJklbyLPU
@GRIBio #IPF #IdiopathicPulmonaryFibrosis #VirtualInvestor $GRI
Innovation can begin with improving everyday life.
CEO Robert Berman shares why bringing new treatment options to patients with severe deep venous insufficiency remains the company's focus.
Watch the Virtual Investor Why Now Series: https://t.co/033bnZrPZx
@enVVenoMed $NVNO #VenousDisease #CVD #CVI #VenousCare #VirtualInvestor